^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Cancer

    Related cancers:
    19h
    Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    19h
    MRD-GC: ctDNA-MRD Monitoring After Resection in Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=110, Recruiting, Peking University | Active, not recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    20h
    NeoART: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=36, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Suspended --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • oxaliplatin
    20h
    NIVO402025: Phase II Open-lable Single-center Clinical Study of the Efficacy and Safety of Low-dose Immunotherapy in the Treatment of Patients With Metastatic and Locally Advanced Colorectal and Gastric Cancers With Microsatellite Unstable Phenotype (MSI)/Deficiency of Mismatch Repair System (dMMR) (clinicaltrials.gov)
    P2, N=128, Enrolling by invitation, Blokhin's Russian Cancer Research Center
    New P2 trial • Mismatch repair • dMMR
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • 5-fluorouracil
    23h
    Supportive Oncology Care At Home RCT (clinicaltrials.gov)
    P=N/A, N=300, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    1d
    Pretreatment multiphasic contrast-enhanced CT predicts tumor regression grade and survival in locally advanced gastric cancer. (PubMed, Abdom Radiol (NY))
    Pretreatment CECT-derived quantitative features can predict TRG response in LAGC, and a combined clinical-imaging model improves predictive performance. Higher normalized enhancement rates in the venous and delayed phases are associated with poorer overall survival, supporting pre-treatment risk stratification in clinical practice.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    1d
    Pharmacological Mechanisms and Clinical Applications of Oxycodone in Cancer Pain Management: A Narrative Review. (PubMed, Drug Des Devel Ther)
    The limitations of oxycodone in chronic neuropathic and bone metastasis pain are discussed, alongside recent advances in oxycodone formulation development and novel analgesics in China. Individualized treatment strategies integrating pharmacogenomic profiles and multimodal approaches are encouraged.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    1d
    Correlation of immune-inflammatory and tumor markers with lymph node metastasis in gastric cancer. (PubMed, Am J Transl Res)
    The combination of CEA, CA724, NLR, and IL-6 serves as an effective preoperative predictor of LNM in GC. The nomogram model based on these markers provides a reliable, non-invasive tool for individualized risk assessment and treatment planning.
    Journal
    |
    IL6 (Interleukin 6) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CA 19-9 (Cancer antigen 19-9) • CRP (C-reactive protein)
    1d
    Banxia Xiexin Decoction inhibits chemoresistance in gastric cancer by regulating BMSC-derived exosome-mediated G3BP1-YWHAZ protein interaction. (PubMed, Am J Transl Res)
    BMSC-derived exosomes promote oxaliplatin resistance in GC through activation of the G3BP1-YWHAZ axis. BXD restores chemosensitivity by interfering with this exosome-mediated pathway, supporting its use as a potential adjuvant strategy to overcome chemotherapy resistance.
    Journal
    |
    G3BP1 (G3BP Stress Granule Assembly Factor 1) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta)
    |
    oxaliplatin
    1d
    Remimazolam impairs bone marrow mesenchymal stem cell function and attenuates the tumor-promoting ability. (PubMed, Am J Transl Res)
    In conclusion, remimazolam exerts stronger inhibitory effects on the stemness and paracrine function of BMMSCs than propofol, thereby reducing their tumor-promoting capacity to a greater extent. Our study focuses on remimazolam and provides experimental evidence for the rational clinical application of anesthetics.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    1d
    Clinicopathological characteristics and outcomes of gastric-type adenocarcinoma of the cervix: a systematic review. (PubMed, AJOG Glob Rep)
    GAS is a rare, distinct, and highly aggressive cervical adenocarcinoma with poor long-term outcomes and limited responsiveness to standard therapy. Improved diagnostic strategies and tailored treatment protocols are urgently needed.
    Review • Journal
    |
    MUC6 (Mucin 6)